We hypothesized that if tau PET is positive only in Aβ(+) individuals with AD-relevant cognitive decline, then in cases of isolated Aβ(+), cognitive decline could be associated with changes within the AD spectrum (i.e., the presence of Aβ pathology) in a mixed pathology context. The gene discussed is MAPT; the disease is Alzheimer disease.